Management of Fever in Neutropenic Patients with Different Risks of Complications
Citations Over TimeTop 10% of 2004 papers
Abstract
Risk stratification of febrile neutropenic patients can have important implications in terms of management. The first prospectively validated risk scoring system was developed in 1992. A subsequent scoring system was developed in 2000, in which a score of ⩽21 predicts a <5% risk for severe complications. Oral combination therapy in an ambulatory or home care setting is acceptable for low-risk patients. Hospital admission is mandatory for high-risk patients. Intravenous monotherapy can be given if neutropenia is anticipated to be of short duration; it is also acceptable if neutropenia is expected to be more prolonged but the patients is stable and do not have an infectious focus. All other patients should receive combination therapy with an aminoglycoside, if infection with a gram-negative pathogen is suspected, or a glycopeptide, if a gram-positive organism is suspected. However, antimicrobial therapy with coverage against gram-negative organisms should always be provided because of the significant mortality associated with these infections.
Related Papers
- Hematologic Conditions: Leukopenia.(2019)
- The etiology and management of leukopenia.(1984)
- [Clinical significance of leukopenia and neutropenia patients with chronic hepatitis "C" in the various regimes antiretroviral therapy].(2010)
- [Effects of cepharanthin on leukopenia and thrombocytopenia induced by chemotherapy in lung cancer patients].(1992)
- Dynamic Effect of Heiliangchongji (HLCJ) on Leukopenia and Neutropenia Introduced by Cyclophosphamide in Mice(2004)